An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of ...

New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing ...

Managing high blood pressure is essential for reducing the risk of heart disease and stroke, which are among the leading ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

0:09 | NKT-2152 is a HIF-2α inhibitor, so it will bind to HIF-2α to prevent heterodimerization with HIF-1 beta. And this is ...

The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

Skye launched its Phase 2 trial of nimacimab in obesity in August 2024. This trial, which is the first to also assess a GLP-1/CB1 inhibitor combination, is expected to report interim weight loss data ...

Summit shared data from the HARMONi-2 study at the World Conference on Lung Cancer (WCLC) conference in San Diego.